The Global "Acute Myeloid Leukemia Therapeutics Market" is forecasted to grow at a CAGR of 13.5 % during the forecast period.(2022-2029)
Acute myeloid leukemia (AML) is also known as acute myelogenous leukemia, acute myeloblastic leukemia, acute granulocytic leukemia, or acute non-lymphocytic leukemia. In acute myeloid leukemia, there is a rapid production of abnormal white blood cells that get collected in the bone marrow and disturb the production of normal blood cells. White blood cells guard the body against infections caused by bacteria.
The global acute myeloid leukaemia therapeutics market growth is driven by the high incidence and prevalence of acute myeloid leukemia, advancements in pharmacology and molecular biology to promote drug development, and increasing investments in R&D by the pharmaceutical companies.
High incidence and prevalence of acute myeloid leukemia will drive the market growth
The increasing prevalence of leukemia across the globe represents one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such disorders, is also driving the market growth.
The American Cancer Society’s estimates for leukemia in the United States, for 2019, indicates that approximately 61,780 new cases of leukemia and 22,840 deaths from leukemia are expected to occur in the country. Among them, the number of new cases of acute myeloid leukemia (AML) will be around 21,450, from which most of the population will be adults. In terms of mortality, the society has estimated that there will be around 10,920 deaths due to AML, in the country. These statistics shows that there is a huge number of people that are prone to suffer from acute myeloid leukemia, which may directly impact the growth of the AML market in the United States. In addition, the global rise in the incidence of AML, along with increased mortality due to the disease, is expected to create a huge demand for AML therapeutics, thus, augmenting the global AML market.
Additionally, the advent of improved immunotoxins, alkylating agents, monoclonal antibodies and multidrug-resistant modulators is another major growth-inducing factor. These therapeutics offer prolonged results, higher efficacy, early and accurate identification of leukemia cells and reduced chances of cancer relapse. Other factors, including extensive research and development (R&D) activities in the field of oncology, along with significant improvements in the existing healthcare infrastructure, are anticipated to drive the market.
Complications related to chemotherapy is likely to hamper the market growth
Chemotherapy treats acute myeloid lukaemia effectively. But like other treatments, it often causes side effects. The side effects of chemotherapy are different for each person. They depend on the type of cancer, location, drugs and dose, and general health. But because these drugs travel throughout the body, they can affect normal, healthy cells that are fast-growing, too. Damage to healthy cells causes side effects.
The COVID-19 pandemic has negatively impacted healthcare systems globally and majorly on the therapeutics market. As per the article published in Cancer Connect 2020, doctors from Dana Farber Cancer Institute determined that during the COVID-19 pandemic, there was a 46% decrease in the diagnoses of the six most common cancer types including acute myeloid luekaemia. According to the Centers for Disease Control and Prevention (CDC) and many medical professional organizations recommended that cancer screening and other health prevention services, along with elective surgeries, be postponed unless the risks outweighed the benefits and secure the hospital infrastructure for the treatment of COVID-19 patients. Thus, the COVID-19 pandemic has impacted the acute myeloid luekaemia market.
Cytarabine segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)
Cytarabine has the largest market size in the forecast period. Most of the times, surgery and radiation therapy in cancer patients remove, kill, or damage cancer cells in a certain area, but chemotherapy works throughout the whole body and gives better results. Chemotherapy is necessary to kill the cancer cells that are spread (metastasized) across different parts of the body. On the contrary, surgery and radiation only attack or kill the tumor that is located in a specific part. Since cancer is the disease which, most of the times, spreads across the whole body in a short period of time, oncologists choose to perform chemotherapy for better results.
Cytarabine is used to treat different forms of leukemia, including acute and chronic myelogenous leukemia (AML and CML), acute lymphocytic leukemia (ALL), and acute promyelocytic leukemia (APL). It is also used to treat Hodgkin's lymphoma, as well as meningeal leukemia and other types of lymphoma (cancers found in the lining of the brain and spinal cord). Due to its effectiveness in the treatment of acute myeloid leukemia, cytarabine is being widely used during chemotherapy. Organizations that are working for cancer, such as Macmillan Cancer Support, have stated that cytarabine is more effective for acute myeloid leukemia, which is why the drug is used widely; therefore, this sub-segment is expected to have a large market share in the chemotherapy segment.
North America region holds the largest market share of global acute myeloid leukaemia therapeutics market
North America is dominating the global acute myeloid leukemia therapeutics market, due to the increasing regulatory approval for acute myeloid leukemia therapeutics. For instance, in November 2018, Astellas Pharma Inc. have received the U.S. Food and Drug Administration (FDA) approved XOSPATA (generic name: gilteritinib) for the treatment of adult patients who have relapsed or refractory (resistant to treatment) Acute Myeloid Leukemia (AML). XOSPATA is an oral therapy and the first and only FLT3-targeting therapy to be approved. In April 2017, Novartis, have received the US Food and Drug Administration (FDA) approval for Rydapt (midostaurin, formerly PKC412) for the treatment of acute myeloid leukemia (AML).
The United States holds the largest share of the market. The United States has a unique healthcare system among the developed countries. However, the cost of hospitals is very high in the country; the government or private insurance cover it. Most of the people opt for private insurance as government insurance has its own limitations. The American Cancer Society had estimated around 21,380 new cases of acute myeloid leukemia (AML) and approximately 10,590 deaths from AML in the United States, in 2016.
According to this society, these statistics involve a large percentage of the adult population. The increasing number of AML patients in the United States require proper medical procedures to increase their life expectancy. The rising prevalence of AML in the country is the prime factor responsible for the growth of the market in the country. and reimbursement policies for cataract treatments is driving the revenue generation in the market.
The acute myeloid leukaemia therapeutics market is moderately competitive presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Novartis AG, Teva Pharmaceuticals, Pfizer, Bristol Myer Squibb, Sanofi-Aventis (Genzyme Corporation), F. Hoffmann-La Roche Ltd, Sunesis Pharmaceuticals Inc., Astellas Pharma, Genmab AS, Otsuka Holdings Co., Ltd among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the acute myeloid leukaemia therapeutics market globally. For instance, in August 2017, Celgene Corporation and Agios Pharmaceuticals, Inc. have received approval for IDHIFA (enasidenib) from the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory AML (R/R AML) with an isocitrate dehydrogenase-2 (IDH2). IDHIFA, is an oral targeted inhibitor of the IDH2 enzyme.
Pfizer Inc. (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products. Its global portfolio includes medicines and vaccines.
DAURISMO Tablets (GLASDEGIB): Daurismo is an oral prescription medicine that is used with the medicine cytarabine to treat newly diagnosed acute myeloid leukemia (AML) in adults who are 75 years of age or older, or have other medical conditions that prevent the use of standard chemotherapy.
Get your free sample proposal with a single click!